BR112017014419A2 - diagnose e tratamento de diabetes incipiente - Google Patents

diagnose e tratamento de diabetes incipiente

Info

Publication number
BR112017014419A2
BR112017014419A2 BR112017014419A BR112017014419A BR112017014419A2 BR 112017014419 A2 BR112017014419 A2 BR 112017014419A2 BR 112017014419 A BR112017014419 A BR 112017014419A BR 112017014419 A BR112017014419 A BR 112017014419A BR 112017014419 A2 BR112017014419 A2 BR 112017014419A2
Authority
BR
Brazil
Prior art keywords
incipient
phosphatase
diseases
diabetes
diagnosis
Prior art date
Application number
BR112017014419A
Other languages
English (en)
Inventor
S Malo Madhu
Original Assignee
S Malo Madhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Malo Madhu filed Critical S Malo Madhu
Publication of BR112017014419A2 publication Critical patent/BR112017014419A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1216—Other enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

é descrito um método para predizer o diabetes incipiente, os distúrbios metabólicos ou a síndrome metabólica pelo desenvolvimento de um perfil temporal individual da fosfatase, que é gerado por medição da concentração de fosfatase nas fezes em um único ponto de tempo ou em múltiplos pontos de tempo. o perfil da fosfatase adicionalmente pode ser usado para diagnosticar e determinar o prognóstico de outras doenças incipientes ou aparentes, tais como a síndrome metabólica, a doença cardíaca coronária, a doença do fígado gorduroso não alcoólico, os cânceres, outras doenças crônicas ou agudas ou doenças infecciosas. também é descrita uma dose específica de fosfatase para uso terapêutico em diabetes incipiente e outras doenças incipientes ou aparentes.
BR112017014419A 2015-01-09 2015-11-17 diagnose e tratamento de diabetes incipiente BR112017014419A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101751P 2015-01-09 2015-01-09
PCT/US2015/061017 WO2016111752A1 (en) 2015-01-09 2015-11-17 Diagnosis and treatment of incipient diabetes

Publications (1)

Publication Number Publication Date
BR112017014419A2 true BR112017014419A2 (pt) 2018-01-16

Family

ID=56356286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014419A BR112017014419A2 (pt) 2015-01-09 2015-11-17 diagnose e tratamento de diabetes incipiente

Country Status (10)

Country Link
US (1) US10781470B2 (pt)
EP (1) EP3242954A4 (pt)
JP (1) JP2018509885A (pt)
KR (1) KR20170103865A (pt)
CN (1) CN107109465A (pt)
AU (1) AU2015375466A1 (pt)
BR (1) BR112017014419A2 (pt)
CA (1) CA2967377A1 (pt)
SG (1) SG11201703704PA (pt)
WO (1) WO2016111752A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11953501B2 (en) 2016-08-04 2024-04-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to detect gastrointestinal disease
WO2018027179A1 (en) * 2016-08-04 2018-02-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to detect gastrointestinal disease
WO2019139891A1 (en) * 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3920713A4 (en) * 2019-02-04 2022-11-09 The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL DISEASES
US20220257726A1 (en) * 2019-07-18 2022-08-18 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
CN111289456B (zh) * 2020-03-31 2023-04-07 西安交通大学第二附属医院 一种检测粪便及肠道组织中肠碱性磷酸酶iap的方法
CN112086194A (zh) * 2020-09-14 2020-12-15 东南大学附属中大医院 一种新发2型糖尿病评分预测系统
CN112394102B (zh) * 2020-11-05 2023-05-26 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用
KR102583808B1 (ko) * 2021-03-05 2023-09-26 경희대학교 산학협력단 눈물을 이용한 당뇨병의 진단 방법 및 키트
WO2023230468A1 (en) * 2022-05-24 2023-11-30 Theriva Biologics, Inc. Ulcerative colitis treatments in selected patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281251A3 (en) * 1987-02-04 1988-09-28 International Immunoassay Laboratories, Inc. A method for preparing a fecal sample composition for immunoassay testing
JP4353799B2 (ja) * 2001-10-09 2009-10-28 ザ・ジョーンズ・ホプキンス・ユニバーシティ 転移に関連するホスファターゼ
US20040096923A1 (en) * 2002-11-15 2004-05-20 Echelon Biosciences Incorporated Lipid phosphatase assays in disease and drug discovery
EP1713541B1 (en) * 2004-02-04 2017-03-22 AM-Pharma B.V. Use of alkaline phosphatase for the detoxification of lps
US20090123951A1 (en) * 2005-12-28 2009-05-14 Gene Friesen Kim Method Of Diagnosing A Body Weight Condition Or Predisposition
EP2334306B1 (en) * 2008-08-29 2014-04-02 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
US20130251701A1 (en) * 2010-10-22 2013-09-26 Zoltan Kiss Consulting Alkaline phosphatase to correct insulin resistance, hyperinsulinemia, and dyslipidemia
WO2012078308A1 (en) * 2010-11-10 2012-06-14 Halushka Perry V Devices and methods for concentration and analysis of fluids

Also Published As

Publication number Publication date
SG11201703704PA (en) 2017-06-29
CN107109465A (zh) 2017-08-29
US10781470B2 (en) 2020-09-22
US20160201110A1 (en) 2016-07-14
AU2015375466A1 (en) 2017-05-25
CA2967377A1 (en) 2016-07-14
KR20170103865A (ko) 2017-09-13
WO2016111752A1 (en) 2016-07-14
EP3242954A1 (en) 2017-11-15
JP2018509885A (ja) 2018-04-12
EP3242954A4 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
BR112017014419A2 (pt) diagnose e tratamento de diabetes incipiente
BR112018070971A2 (pt) métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia
BR112014008597A2 (pt) sistema e método para determinação dos pontos q e j de um eletrocardiograma (ecg); um ou mais processadores; e mídia executável por computador não transitória
BR112017005730A2 (pt) predição de evento de risco cardiovascular e usos da mesma
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
BR112015018213A8 (pt) métodos para determinar a síndrome da angústia respiratória aguda (ards) e para monitorar o desenvolvimento desta e kit para diagnóstico".
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112014004685A2 (pt) métodos e aparelho para determinar as condições de linhas de energia
BR112012022943A2 (pt) inibidores de syk de imidazopiridnas
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
BR112017025459A2 (pt) composição, método para tratamento de doença falciforme, kit, método para detecção de polissulfato pentosano de sódio (pps)
BR112014004336A2 (pt) sistema e método para estimar a quantidade de interesse de um sistema de artéria / tecido / veia dinâmico
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112016006556A2 (pt) arranjos detectáveis, sistemas para diagnóstico, e métodos para produzir e usar os mesmos
BR112018008799A2 (pt) método de prognóstico
BR112019000946A8 (pt) Compostos para imagiologia dos agregados da proteína tau
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
BR112017028627A2 (pt) dispositivo para detectar proteínas deformadas e métodos de uso mesmo
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]